CN100488979C - 甘草次酸-30-酰胺类衍生物及其用途 - Google Patents

甘草次酸-30-酰胺类衍生物及其用途 Download PDF

Info

Publication number
CN100488979C
CN100488979C CNB2005100153718A CN200510015371A CN100488979C CN 100488979 C CN100488979 C CN 100488979C CN B2005100153718 A CNB2005100153718 A CN B2005100153718A CN 200510015371 A CN200510015371 A CN 200510015371A CN 100488979 C CN100488979 C CN 100488979C
Authority
CN
China
Prior art keywords
methyl
isoxazol
glycyrrhetinic acid
isoxazole
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005100153718A
Other languages
English (en)
Chinese (zh)
Other versions
CN1948332A (zh
Inventor
王建武
徐为人
雍建平
汤立达
张士俊
刘利军
王玉丽
任晓文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Institute of Pharmaceutical Research Co Ltd
Original Assignee
Tianjin Institute of Pharmaceutical Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CNB2005100153718A priority Critical patent/CN100488979C/zh
Application filed by Tianjin Institute of Pharmaceutical Research Co Ltd filed Critical Tianjin Institute of Pharmaceutical Research Co Ltd
Priority to AT06791264T priority patent/ATE477019T1/de
Priority to US12/090,169 priority patent/US7790759B2/en
Priority to ES06791264T priority patent/ES2350053T3/es
Priority to EP06791264A priority patent/EP1935892B1/en
Priority to JP2008534857A priority patent/JP5286087B2/ja
Priority to AU2006301708A priority patent/AU2006301708B2/en
Priority to DE602006016146T priority patent/DE602006016146D1/de
Priority to PCT/CN2006/002711 priority patent/WO2007041969A1/zh
Publication of CN1948332A publication Critical patent/CN1948332A/zh
Application granted granted Critical
Publication of CN100488979C publication Critical patent/CN100488979C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB2005100153718A 2005-10-14 2005-10-14 甘草次酸-30-酰胺类衍生物及其用途 Expired - Fee Related CN100488979C (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CNB2005100153718A CN100488979C (zh) 2005-10-14 2005-10-14 甘草次酸-30-酰胺类衍生物及其用途
US12/090,169 US7790759B2 (en) 2005-10-14 2006-10-16 Glycyrrhetinic acid-30-amide derivatives and their use
ES06791264T ES2350053T3 (es) 2005-10-14 2006-10-16 Derivados de ácido-30-amida glicirretínico y usos de los mismos.
EP06791264A EP1935892B1 (en) 2005-10-14 2006-10-16 Glycyrrhetinic acid-30-amide derivatives and the uses thereof
AT06791264T ATE477019T1 (de) 2005-10-14 2006-10-16 Glycyrrhetinsäure-30-amidderivate und anwendungen davon
JP2008534857A JP5286087B2 (ja) 2005-10-14 2006-10-16 新規グリチルレチン酸−３０−アミド誘導体及びその用途
AU2006301708A AU2006301708B2 (en) 2005-10-14 2006-10-16 Glycyrrhetinic acid-30-amide derivatives and the uses thereof
DE602006016146T DE602006016146D1 (de) 2005-10-14 2006-10-16 Glycyrrhetinsäure-30-amidderivate und anwendungen davon
PCT/CN2006/002711 WO2007041969A1 (fr) 2005-10-14 2006-10-16 Dérivés d'acide glycyrrhétinique-30-amide et applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100153718A CN100488979C (zh) 2005-10-14 2005-10-14 甘草次酸-30-酰胺类衍生物及其用途

Publications (2)

Publication Number Publication Date
CN1948332A CN1948332A (zh) 2007-04-18
CN100488979C true CN100488979C (zh) 2009-05-20

Family

ID=37942322

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100153718A Expired - Fee Related CN100488979C (zh) 2005-10-14 2005-10-14 甘草次酸-30-酰胺类衍生物及其用途

Country Status (9)

Country Link
US (1) US7790759B2 (https=)
EP (1) EP1935892B1 (https=)
JP (1) JP5286087B2 (https=)
CN (1) CN100488979C (https=)
AT (1) ATE477019T1 (https=)
AU (1) AU2006301708B2 (https=)
DE (1) DE602006016146D1 (https=)
ES (1) ES2350053T3 (https=)
WO (1) WO2007041969A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101229172B (zh) * 2007-12-28 2010-10-27 天津药物研究院 甘草次酸30-酰胺类衍生物的固体分散物、其制备方法和用途
WO2009090063A1 (en) * 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CN101899081B (zh) * 2009-05-31 2012-09-05 江苏正大天晴药业股份有限公司 甘草次酸酯类衍生物合成方法以及脱氧甘草次酸酯化合物
CN102653550A (zh) * 2011-03-01 2012-09-05 广西壮族自治区药用植物园 甘草次酸的制备及用途
CN102250187B (zh) * 2011-04-25 2013-03-27 北京中海康医药科技发展有限公司 一种甘草次酸衍生物及其制备方法
CN102241726B (zh) * 2011-05-27 2013-06-12 苏州大学 甘草次酸衍生物及其作为抗肿瘤药物的应用
CN102813661B (zh) * 2011-06-09 2014-04-09 天津药物研究院 一种甘草次酸衍生物的用途
TWI424839B (zh) 2011-10-27 2014-02-01 Univ Kaohsiung Medical 18β－甘草次酸衍生物及其用途
CN103102383A (zh) * 2011-11-14 2013-05-15 天津药物研究院 甘草次酸-30-酰胺类衍生物的晶型a及其制备方法
CN103102382A (zh) * 2011-11-14 2013-05-15 天津药物研究院 甘草次酸-30-酰胺类衍生物的晶型b及其制备方法
CN102579462B (zh) * 2012-01-18 2013-05-22 苏州大学 甘草次酸衍生物制备抗炎药物中的应用
CN102838651B (zh) * 2012-09-26 2014-05-28 天津药物研究院 一类齐墩果酸的衍生物及其制备方法和用途
WO2015076325A1 (ja) * 2013-11-25 2015-05-28 国立大学法人名古屋大学 グリチルレチン酸誘導体及びその利用
US9896476B1 (en) 2017-09-21 2018-02-20 King Saud University Glycyrrhetic acid derivatives
CN107619425A (zh) * 2017-09-21 2018-01-23 南京师范大学 一种尾接有机导向分子的芳基钌配合物及其合成方法和应用
CN110776549B (zh) * 2019-11-25 2021-06-11 烟台大学 含氮杂环甘草次酸衍生物及其制备方法和抗甲型流感病毒应用
CN111018938B (zh) * 2019-12-10 2021-05-25 中国人民解放军第二军医大学 一种五环三萜类甘草次酸衍生物及制备方法与应用
CN118561945A (zh) * 2024-05-22 2024-08-30 厦门稀土材料研究所 18β-甘草次酸酯类衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1447162A (en) * 1974-03-12 1976-08-25 Landerlan Sa Lab Triterpene derivatives
GB1516271A (en) * 1976-03-15 1978-06-28 Biorex Laboratories Ltd Glycyrrhetinic acid derivatives
GB2140809A (en) * 1983-06-01 1984-12-05 Biorex Laboratories Ltd New derivatives of glycyrrhetinic acid
GB0105772D0 (en) * 2001-03-08 2001-04-25 Sterix Ltd Use
DE10307388A1 (de) * 2003-02-21 2004-09-02 Cognis Deutschland Gmbh & Co. Kg Glyzyrrhetinsäureester
AU2004255749B2 (en) * 2003-06-30 2008-12-18 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
CN1257182C (zh) * 2004-04-06 2006-05-24 南开大学 甘草次酸的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Synthesis and pharmacological properties of newheterocyclic and aromatic amides of glycyrrhizic acid". Baltina, L. A. et al.Khim-Farm. Zh.,Vol.30 No.8. 1996 *

Also Published As

Publication number Publication date
DE602006016146D1 (de) 2010-09-23
WO2007041969A1 (fr) 2007-04-19
CN1948332A (zh) 2007-04-18
AU2006301708A1 (en) 2007-04-19
ES2350053T3 (es) 2011-01-17
JP5286087B2 (ja) 2013-09-11
US20080214636A1 (en) 2008-09-04
EP1935892B1 (en) 2010-08-11
ATE477019T1 (de) 2010-08-15
AU2006301708B2 (en) 2011-06-23
EP1935892A1 (en) 2008-06-25
JP2009511511A (ja) 2009-03-19
US7790759B2 (en) 2010-09-07
EP1935892A4 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
CN100488979C (zh) 甘草次酸-30-酰胺类衍生物及其用途
CN106928206A (zh) 醛基类化合物及其制法和用途
CN108685913A (zh) 含氧吡格雷光学异构体或其盐的组合物及制备方法和应用
JP6401249B2 (ja) ２，３−ブタンジアミドエポキシド化合物ならびにその調製方法及び使用
CN110279689B (zh) 一种α-倒捻子素衍生物在制备抗治疗性前列腺增生药物中的应用
JP5932827B2 (ja) チアゾールアミン誘導体および抗ピコルナウイルス感染薬剤としてのその使用
CN105646420A (zh) 一种去氢中美菊素c衍生物及其制备方法和用途
CN115677610B (zh) 苯并噁唑啉酮衍生物及其制备方法和用途
CN106963766B (zh) 一种氮杂螺酮类药物组合物及其制备方法
CN101085793A (zh) 一类具有镇静活性的含1,3,4－噁二唑杂环的豆腐果甙新药及其制备方法
SE455420B (sv) Anvendning av 4-fenyl-4-oxo-butensyraderivat for framstellning av ett lekemedel for behandling av magakommor och gastroduodenala akommor i samband med hyperaciditet
CN102391332B (zh) 一种保肝化合物及其制备方法和用途
CN119707740B (zh) 一种白藜芦醇亚胺衍生物及其制备方法和应用
CN120241755B (zh) 一种用于治疗多发性肺结节的丙酮酸盐吸入雾化剂及其制备方法
CN119039135B (zh) 羧基查尔酮类衍生物及其制备方法与应用
CN102250085B (zh) 联苯双酯衍生物及其在制备自身免疫性疾病药物中的应用
CN117682966B (zh) 一种手性芳基丙酸衍生物及其药物组合物和用途
CN113277980B (zh) 托伐普坦杂质及其制备方法
CN104045636B (zh) 黄连碱卤酸盐的合成方法及其用途
CN110028464B (zh) 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用
CN112094255B (zh) 一种灯盏花乙素苷元衍生物、其制备方法与应用
CN102030808B (zh) 具有抗炎镇痛功效的茶皂苷元衍生物及其制备方法与应用
JPS601303B2 (ja) 新規オキシムエ−テル化合物およびその塩類
CN101307080A (zh) 具有镇静活性的5-(4-β-D-吡喃阿洛糖苷-苯基)-3-芳基-4,5-二氢吡唑-1-硫代酰胺类化合物的制备
WO2009003307A1 (fr) Dérivés de phtiobuzonum et préparation, composition pharmaceutique et utilisation de ceux-ci

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090520

Termination date: 20211014